BioCryst CBO Megan Sniecinski departs Aug 9; severance of $658,634 plus accelerated option vesting

BIOCRYST PHARMACEUTICALS INC

Megan Sniecinski, Chief Business Officer, separates effective August 9, 2021; previously disclosed on Aug 3.
Severance payment of $658,634.04 paid in equal installments over one year.
100% of unvested options from July 2019 & Dec 2019, and 75% from Dec 2020, accelerate to vested.
COBRA premiums paid for up to 18 months; 180-day post-separation option exercise window.
Agreement includes one-year non-compete in therapeutic areas (HAE, FOP, PNH, etc.) and non-solicitation.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Megan Sniecinski

Chief Business Officer

BCRX · BIOCRYST PHARMACEUTICALS INC

Effective: 2021-08-09
Filed: August 9, 2021, 7:59 PM ET

Megan Sniecinski, Chief Business Officer of the Company, would separate from employment with the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Megan Sniecinski departed as Chief Business Officer at BIOCRYST PHARMACEUTICALS INC.

Action: separated
Role: Chief Business Officer

Exact text from the filing

Megan Sniecinski, Chief Business Officer of the Company, would separate from employment with the Company.

View on SEC.gov

BIOCRYST PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001171843-21-005671

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.